values (PPVs) as shown in Table 1 [6, 7] . EIS is approved for clinical use, but how the EIS score should be interpreted and used in clinical practice is still unclear.
At the Department of Dermatology, Sahlgrenska University Hospital, the combination of clinical examination and ST-SDDM after four months has been used in the assessment of AMLs requiring follow-up to determine whether they should be surgically removed or not.
Objectives
The objective of this study was to assess whether EIS in addition to conventional practice (ST-SDDM) could improve the selection of patients with AMLs needing surgery. The secondary objective was to determine the correlation between dermoscopic changes and EIS scores during short-term monitoring of AMLs.
Methods
In February 2015, EIS was introduced into clinical practice in combination with ST-SDDM at the Department of Dermatology, Sahlgrenska University Hospital. In this retrospective descriptive study, the clinical outcome of all patients with AMLs that were followed with ST-SDDM combined with EIS measurements during the period from February 1 to June 30, 2015, were analyzed. The Regional Ethical Review Board assessed the study as a retrospective appraisal of quality of care and therefore had no objections to the study.
All patients over the age of 18 years diagnosed with an AML and monitored with ST-SDDM and EIS during the study period were considered eligible. Patients lost to follow-up, not meeting EIS measurement criteria (see below), having insufficient patient notes or with dermoscopic images of poor quality were excluded. Certain criteria must be met for EIS measurements to be valid. The lesion must have a
Background
The concept of an atypical melanocytic lesion (AML) can be applied to any pigmented lesion in which the clinical and dermoscopic criteria are sufficient to classify it as melanocytic, but are insufficient to determine whether the lesion is a benign nevus or an early stage of melanoma. When patients present with one or more AMLs, excision for histopathological diagnosis may be necessary, but more advanced non-invasive diagnostic methods might be preferred.
Dermoscopy is a technique that uses a handheld magnifying device combined with either the application of immersion fluid between the transparent plate of the device and the skin or the use of cross-polarized light. This technique allows for visualization of diagnostic features of skin lesions not visible to the naked eye. It is a tool that helps the clinician to assess and differentiate between melanocytic and non-melanocytic lesions and determine whether they are benign or malignant. Several diagnostic algorithms can be used (e.g., pattern analysis, 7-point checklist, ABCD, Menzies' scoring method) [1, 2] . Although dermoscopy is a very good complement to clinical evaluation, there will always be some lesions that lead to diagnostic uncertainty. To be able to identify and monitor these lesions without unnecessary excision, the use of shortterm sequential digital dermoscopic monitoring (ST-SDDM) is valuable [3] . how EIS measurements are performed have been published earlier [6, 7] .
Since the specificity and the positive predictive value of EIS measurements from previous studies were considered too low to be clinically applicable, the authors suggested a novel algorithm for the clinical management based on the EIS score. A greater emphasis was placed on the clinical and dermoscopic evaluation of lesions than on the EIS scores. The patients returned after four months for a follow-up visit during which new clinical and dermoscopic images were taken and Nevisense ® measurements were performed. The presence or absence of dermoscopic changes were visualized by comparing the two dermoscopic images on a digital monitor.
The management algorithm is presented in Figure 1 . If the EIS score at visit 1 was 9 or 10, the lesion was excised regardless of the dermoscopic assessment. Otherwise, the AML(s)
were followed up after four months. At follow-up, the dermoscopic images from both visits were compared. If dermoscopic changes were observed (e.g., growing or thickened network, new or bigger globules, new or growing negative network), the lesion was excised regardless of the EIS score at visit 2. Statistical analyses were made to determine the sensitivity, specificity, PPV and NPV of the method.
Results
A total of 19 patients (12 women and 7 men) with 22 AMLs were examined with both ST-SDDM and EIS during the study period ( Table 2 ). The short-term interval between visits ranged from 3.5-4 months. The median age of the patients was 53 years (range 23 to 69 years).
diameter of 2-20 mm, the skin must be intact (i.e., lesions are not ulcerated or bleeding), and the lesion should be free of scars or fibrosis and located in skin areas free from eczema, psoriasis, acute sunburn or terminal hair. Furthermore, the lesion should not be located in specific anatomical areas, such as acral skin, genitals, eyes or mucous membranes.
After a full-body skin examination, the physician decided which suspected AML(s) should be followed using ST-SDDM and EIS. First, a clinical and a dermoscopic image were taken with a Canon Digital Camera PowerShot G12, G15 or G16 In 10 cases (45%), the difference in EIS scores was ≥2 points and differences up to ± 4 points were observed.
If the algorithm provided by the manufacturer had been followed, 19
AMLs would have been considered suspicious and excised. Of these, only one was malignant. Thus, in this very limited sample, and assuming that the nonexcised lesions were correctly diagnosed using ST-SDDM, the positive predictive value (PPV) of EIS alone was 5.3% and the specificity was 14.3%. The sensitivity and negative predictive value (NPV) were both 100%.
Conclusions
Melanoma affects more than 3700 people in Sweden each year. After nonmelanoma skin cancer, malignant melanoma is the cancer type whose incidence The EIS scores at day 0 and at follow-up showed a rather high variability. is increasing most in Sweden [8] . Melanoma detection often poses a challenge in equivocal lesions or in patients with many AMLs. As early detection of melanoma is vital for treatment outcome and survival [9, 10] There are several limitations to this study. The study was retrospectively additional techniques could perhaps increase the specificity when analyzing AMLs. For example, a study on the combination of EIS with near-infrared (NIR) spectroscopy for analyzing melanocytic lesions provided a specificity of 95%, albeit with a lower sensitivity of 83% [11] .
Regarding the term AML that we use in this study, we
propose that this term should replace the incorrectly used term of a clinically suspected "dysplastic nevus" which is unfortunately used by too many dermatologists today. A "dysplastic" nevus is a variant of a benign melanocytic nevus, which can only be diagnosed histopathologically with typical architectural disorder and varying degrees of nuclear atypia in intraepidermal melanocytes [12, 13] . EIS measurements on AMLs showed lower specificity compared with previous studies on EIS [5] [6] [7] . This may be due to the fact that the inclusion criteria in this study were different and that the sample size was smaller. Consequently, the studies cannot be directly compared. EIS combined with nosis of a melanocytic lesion is uncertain, the lesion should therefore be called an AML until the diagnosis is confirmed clinically with ST-SDDM or histopathologically after a complete excision of the lesion.
In this pilot study, the addition of EIS to ST-SDDM using a modified EIS algorithm did not identify additional pathological lesions. Instead, some histopathologically benign lesions were needlessly excised. In addition, there was no correlation between dermoscopic changes seen with ST-SDDM and significantly increased EIS scores. Also, the reproducibility of the EIS measurements was lower than expected, which is an issue that needs to be studied further before continuing to use this method in routine care. For now, we can therefore not recommend EIS in the standard management of monitoring AMLs.
